Explore why therapy-related high-risk MDS resists standard HMAs and how azacitidine plus venetoclax aims to improve outcomes and bridge to transplant.
Investigating New Therapies for High-Risk Therapy-Related MDS
Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.
t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies that extend life and preserve quality of life.